Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent

被引：0
|
作者：
Williams, D. [1 ]
Gana, T. [1 ]
Sivapalan, L. [1 ]
Butler, O. [1 ]
Jackson, R. [1 ]
Perez-Mancera, P. [1 ]
Barrera-Briceno, L. [1 ]
Copple, I. [1 ]
Cox, T. [1 ]
Goldring, C. [1 ]
Halloran, C. M. [1 ]
Ghaneh, P. [1 ]
Palmer, D. [1 ]
Strobel, O. [2 ]
Greenhalf, W. [1 ]
Neoptolemos, J. P. [1 ]
Costello, E. [1 ]
机构：
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[2] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany
来源：
PANCREAS | 2017年 / 46卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1443 / 1443
页数：1
相关论文
共 50 条
  • [21] Activation of NRF2 and adaptive resistance to chemotherapy
    Clinton, Sarah A.
    Barbour, Karen W.
    Berger, Franklin G.
    CANCER RESEARCH, 2017, 77
  • [22] NRF2 MUTATION AT RS6721961 AND ITS ASSOCIATION WITH NRF2 TARGET GENES IN BREAST CANCER PATIENTS WITH NO HISTORY OF CHEMOTHERAPY
    Khazaei, M.
    Sajadimajd, S.
    Khazaei, S.
    WORLD CANCER RESEARCH JOURNAL, 2020, 7
  • [23] Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway
    Zhou, Yunjiang
    Zhou, Yang
    Wang, Keke
    Li, Tao
    Yang, Mengdi
    Wang, Rui
    Chen, Yaxin
    Cao, Mengran
    Hu, Rong
    CANCER LETTERS, 2020, 474 : 94 - 105
  • [24] Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
    Ren, Dongmei
    Villeneuve, Nicole F.
    Jiang, Tao
    Wu, Tongde
    Lau, Alexandria
    Toppin, Henry A.
    Zhang, Donna D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (04) : 1433 - 1438
  • [25] Minnelide: Single Chemotherapeutic Agent Against Pancreatic Cancer
    Chugh, R.
    Sangwan, V.
    Borja-Cacho, D.
    Dudeja, V.
    Vickers, S. M.
    Saluja, A. K.
    PANCREAS, 2010, 39 (08) : 1314 - 1315
  • [26] CONTINUOUS NRF2 ACTIVATION SENSITIZES PANCREATIC CANCER CELLS TO GLUTAMATE DEPRIVATION
    Tanaka, Yu
    Hamada, Shin
    Matsumoto, Ryotaro
    Masamune, Atsushi
    GASTROENTEROLOGY, 2020, 158 (06) : S221 - S221
  • [27] Minnelide, a Potent Chemotherapeutic Agent Against Pancreatic Cancer
    Sangwan, V.
    Chugh, R. K.
    Johnson, D. M.
    Banerjee, S.
    Dudeja, V.
    Mujumdar, N.
    Mackenzie, T. N.
    Vickers, S. M.
    Saluja, A. K.
    PANCREAS, 2011, 40 (08) : 1352 - 1352
  • [28] NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
    Chio, Iok In Christine
    Jafarnejad, Seyed Mehdi
    Ponz-Sarvise, Mariano
    Park, Youngkyu
    Rivera, Keith
    Palm, Wilhelm
    Wilson, John
    Sangar, Vineet
    Hao, Yuan
    Oehlund, Daniel
    Wright, Kevin
    Filippini, Dea
    Lee, Eun Jung
    Da Silva, Brandon
    Schoepfer, Christina
    Wilkinson, John Erby
    Buscaglia, Jonathan M.
    DeNicola, Gina M.
    Tiriac, Herve
    Hammell, Molly
    Crawford, Howard C.
    Schmidt, Edward E.
    Thompson, Craig B.
    Pappin, Darryl J.
    Sonenberg, Nahum
    Tuveson, David A.
    CELL, 2016, 166 (04) : 963 - 976
  • [29] NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer
    Chio, Iok In Christine
    Jafarnejad, Seyed Mehdi
    Ponz-Sarvise, Mariano
    Park, Youngkyu
    Rivera, Keith
    Palm, Wilhelm
    Ohlund, Daniel
    Hammell, Molly
    Crawford, Howard
    Schmidt, Edward
    Thompson, Craig
    Pappin, Darryl
    Sonenberg, Nahum
    Tuveson, David
    CANCER RESEARCH, 2017, 77
  • [30] dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer
    Hu, Qiangsheng
    Qin, Yi
    Xiang, Jinfeng
    Liu, Wensheng
    Xu, Wenyan
    Sun, Qiqing
    Ji, Shunrong
    Liu, Jiang
    Zhang, Zheng
    Ni, Quanxing
    Xu, Jin
    Yu, Xianjun
    Zhang, Bo
    CELL PROLIFERATION, 2018, 51 (04)
12345